

**GSK plc (the 'Company')**  
Transaction notification

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
<b>2.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	770
		£16.2900	1,279
		£16.2900	1,446
d)	Aggregated information		
	Aggregated volume	3,495	
	Price	£16.2900	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>	
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/ amendment	Initial notification

<b>2.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 on ADSs held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		\$40.8000	427
d)	Aggregated information		
	Aggregated volume		
	Price		
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>		
a)	Name	Julie Brown	
b)	Position/status	Chief Financial Officer	
c)	Initial notification/ amendment	Initial notification	
<b>2.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	551
d)	Aggregated information		

	Aggregated volume Price	
e)	Date of the transaction	2024-04-16
f)	Place of the transaction	London Stock Exchange (XLON)

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>		
a)	Name	Diana Conrad	
b)	Position/status	Chief People Officer	
c)	Initial notification/ amendment	Initial notification	
<b>2.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	120
		£16.2900	232
		£16.2900	364
d)	Aggregated information		
	Aggregated volume Price	716 £16.2900	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
<b>2.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		

a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	148
		£16.2900	226
		£16.2900	369
d)	Aggregated information		
	Aggregated volume	743	
	Price	£16.2900	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communications and CEO Office	
c)	Initial notification/ amendment	Initial notification	
<b>2.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	69
		£16.2900	141
		£16.2900	228

d)	Aggregated information	
	Aggregated volume	438
	Price	£16.2900
e)	Date of the transaction	2024-04-16
f)	Place of the transaction	London Stock Exchange (XLON)

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>		
a)	Name	Luke Miels	
b)	Position/status	Chief Commercial Officer	
c)	Initial notification/ amendment	Initial notification	
<b>2.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	253
		£16.2900	545
		£16.2900	687
d)	Aggregated information		
	Aggregated volume	1,485	
	Price	£16.2900	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>		
a)	Name	Shobie Ramakrishnan	
b)	Position/status	Chief Digital and Technology Officer	
c)	Initial notification/ amendment	Initial notification	

1)	Initial notification/ amendment		
2.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 on ADSs held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		\$40.8000	26
		\$40.8000	112
		\$40.8000	175
d)	Aggregated information		
	Aggregated volume	313	
	Price	\$40.8000	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	<b>Details of PDMR/person closely associated with them ('PCA')</b>		
a)	Name	David Redfern	
b)	Position/status	President Corporate Development	
c)	Initial notification/ amendment	Initial notification	
2.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)

		£16.2900	167
		£16.2900	315
		£16.2900	437
d)	Aggregated information		
	Aggregated volume	919	
	Price	£16.2900	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>		
a)	Name	Regis Simard	
b)	Position/status	President, Global Supply Chain	
c)	Initial notification/ amendment	Initial notification	
<b>2.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	152
		£16.2900	253
		£16.2900	526
d)	Aggregated information		
	Aggregated volume	931	
	Price	£16.2900	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>
-----------	--

a)	Name	Philip Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
<b>2.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	105
		£16.2900	165
		£16.2900	294
d)	Aggregated information		
	Aggregated volume	564	
	Price	£16.2900	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK	
c)	Initial notification/ amendment	Initial notification	
<b>2.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	



b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	111
		£16.2900	403
		£16.2900	455
d)	Aggregated information		
	Aggregated volume	969	
	Price	£16.2900	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>		
a)	Name	Tony Wood	
b)	Position/status	Chief Scientific Officer	
c)	Initial notification/ amendment	Initial notification	
<b>2.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	191
		£16.2900	561
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume	752	
	Price	£16.2900	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

transaction
-------------

<b>1.</b>	<b>Details of PDMR/person closely associated with them ('PCA')</b>		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
<b>2.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</b>		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period	
c)	Price(s) and volume(s)	Price(s) £16.2900	Volume(s) 6863.859
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSFLFLWELSES